What is Skinhealth Systems Inc's earnings per share (EPS)?

Skinhealth Systems Inc (SKIN) reported diluted earnings per share of $-0.16 for fiscal year 2025. This represents a 55.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Skinhealth Systems Inc Financials

SKIN

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Skinhealth Systems Inc (SKIN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SKIN FY2025 2026-05-07

Margin repair and working-capital release are turning a shrinking revenue base into real cash, even as the liquidity cushion thins.

From FY2023 to FY2025, gross margin rebounded from 39.0% to 65.3%, and that repair coincided with operating cash flow staying positive even while earnings remained below breakeven. Because capex was only $303K in FY2025, almost every operating dollar became free cash flow, so the recent cash generation looks more like a lighter operating model than an accounting artifact.

The business is no longer burning cash the way it did in FY2022, but its balance-sheet cushion is much smaller: cash fell from $523M in FY2023 to $233M in FY2025. That helps explain why the current ratio compressed to 1.7x; the company still covers near-term obligations, just with far less excess liquidity than before.

Liabilities of $439M still sit against only $61M of equity, so modest profit improvements have an outsized effect on reported returns and on how much balance-sheet flexibility remains. This is why a near-breakeven income statement matters operationally here: the business looks asset-light on reinvestment, but not yet balance-sheet-light in how it is financed.

Financial Health Signals

Financial Profile 14/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Skinhealth Systems Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Skinhealth Systems Inc has an operating margin of -6.9%, meaning the company retains $-7 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -20.3% the prior year.

Growth

Skinhealth Systems Inc's revenue declined 10% year-over-year, from $334.3M to $300.8M. This contraction results in a growth score of 12/100.

Leverage

Skinhealth Systems Inc has elevated debt relative to equity (D/E of 7.19), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.

Liquidity

Skinhealth Systems Inc's current ratio of 1.66 is below the typical benchmark, resulting in a score of 29/100. However, the company holds substantial cash reserves (125% of current liabilities), which buffers actual liquidity risk. Large mature operators often run tight current ratios by design.

Cash Flow

Skinhealth Systems Inc has a free cash flow margin of 12.4%, earning a moderate score of 46/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Skinhealth Systems Inc generates a -15.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -56.2% the prior year.

Piotroski F-Score Neutral

6/9

Skinhealth Systems Inc passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed

-3.95x

For every $1 of reported earnings, Skinhealth Systems Inc generates $-3.95 in operating cash flow ($37.5M OCF vs -$9.5M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage At Risk

-1.1x

Skinhealth Systems Inc earns $-1.1 in operating income for every $1 of interest expense (-$20.8M vs $19.3M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$300.8M

YoY-10.0%

5Y CAGR+20.4%

Skinhealth Systems Inc generated $300.8M in revenue in fiscal year 2025. This represents a decrease of 10.0% from the prior year.

EBITDA

$33K

YoY+100.1%

Skinhealth Systems Inc's EBITDA was $33K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 100.1% from the prior year.

Net Income

-$9.5M

YoY+67.4%

Skinhealth Systems Inc reported -$9.5M in net income in fiscal year 2025. This represents an increase of 67.4% from the prior year.

EPS (Diluted)

$-0.16

YoY+55.6%

Skinhealth Systems Inc earned $-0.16 per diluted share (EPS) in fiscal year 2025. This represents an increase of 55.6% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$37.2M

YoY+141.8%

Skinhealth Systems Inc generated $37.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 141.8% from the prior year.

Cash & Debt

$232.7M

YoY-37.1%

5Y CAGR+89.6%

Skinhealth Systems Inc held $232.7M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

128M

YoY+2.1%

Skinhealth Systems Inc had 128M shares outstanding in fiscal year 2025. This represents an increase of 2.1% from the prior year.

Margins & Returns

Gross Margin

65.3%

YoY+10.8pp

5Y CAGR+8.9pp

Skinhealth Systems Inc's gross margin was 65.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 10.8 percentage points from the prior year.

Operating Margin

-6.9%

YoY+13.4pp

5Y CAGR+7.5pp

Skinhealth Systems Inc's operating margin was -6.9% in fiscal year 2025, reflecting core business profitability. This is up 13.4 percentage points from the prior year.

Net Margin

-3.2%

YoY+5.5pp

5Y CAGR+21.3pp

Skinhealth Systems Inc's net profit margin was -3.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 5.5 percentage points from the prior year.

Return on Equity

-15.6%

YoY+40.6pp

Skinhealth Systems Inc's ROE was -15.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 40.6 percentage points from the prior year.

Capital Allocation

R&D Spending

$5.6M

YoY-10.6%

5Y CAGR+10.5%

Skinhealth Systems Inc invested $5.6M in research and development in fiscal year 2025. This represents a decrease of 10.6% from the prior year.

Share Buybacks

Skinhealth Systems Inc spent $0 on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

$303K

YoY-59.9%

5Y CAGR-38.7%

Skinhealth Systems Inc invested $303K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 59.9% from the prior year.

SKIN Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$300.8M-10.0%	$334.3M-16.0%	$398.0M+8.8%	$365.9M+40.7%	$260.1M+118.4%	$119.1M
Cost of Revenue	$104.4M-31.3%	$152.0M-37.4%	$242.9M+107.4%	$117.1M+43.6%	$81.5M+57.1%	$51.9M
Gross Profit	$196.4M+7.7%	$182.3M+17.5%	$155.1M-37.7%	$248.8M+39.3%	$178.5M+165.7%	$67.2M
R&D Expenses	$5.6M-10.6%	$6.3M-37.7%	$10.1M+19.6%	$8.4M+3.0%	$8.2M+140.4%	$3.4M
SG&A Expenses	$117.9M-6.0%	$125.5M-4.5%	$131.4M+23.9%	$106.1M+7.5%	$98.7M+222.0%	$30.6M
Operating Income	-$20.8M+69.3%	-$67.8M+48.2%	-$130.9M-406.6%	-$25.8M+35.3%	-$39.9M-132.4%	-$17.2M
Interest Expense	$19.3M+85.6%	$10.4M-23.7%	$13.6M+1.9%	$13.4M+13.7%	$11.8M	N/A
Income Tax	$3.6M+892.3%	-$452K+74.5%	-$1.8M-259.0%	$1.1M+159.5%	-$1.9M+79.9%	-$9.3M
Net Income	-$9.5M+67.4%	-$29.1M+70.9%	-$100.1M-326.5%	$44.2M-88.3%	$378.7M+1398.0%	-$29.2M
EPS (Diluted)	$-0.16+55.6%	$-0.36+52.6%	$-0.76-230.4%	$-0.23+93.8%	$-3.71	$-0.85

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$64.9M-21.2%	$82.4M+16.6%	$70.7M-9.6%	$78.2M+12.4%	$69.6M-16.7%	$83.5M+6.0%	$78.8M-13.0%	$90.6M
Cost of Revenue	$20.5M-30.2%	$29.3M+17.2%	$25.0M-13.9%	$29.1M+38.5%	$21.0M-32.6%	$31.1M-18.4%	$38.2M-23.2%	$49.7M
Gross Profit	$44.4M-16.2%	$53.0M+16.2%	$45.6M-7.1%	$49.1M+1.1%	$48.6M-7.2%	$52.3M+28.8%	$40.6M-0.7%	$40.9M
R&D Expenses	$1.1M-34.4%	$1.7M-1.0%	$1.7M+35.7%	$1.3M+25.4%	$998K-18.3%	$1.2M+10.3%	$1.1M-4.4%	$1.2M
SG&A Expenses	$21.9M-20.7%	$27.7M-5.4%	$29.3M+6.5%	$27.5M-18.2%	$33.6M+5.7%	$31.8M-5.0%	$33.4M+6.5%	$31.4M
Operating Income	-$1.8M-1211.7%	$162K+102.6%	-$6.2M-131.2%	-$2.7M+77.5%	-$12.0M-68.0%	-$7.2M+66.7%	-$21.5M+2.7%	-$22.1M
Interest Expense	$6.3M-0.4%	$6.4M+1.0%	$6.3M+52.3%	$4.1M+65.9%	$2.5M+1.4%	$2.5M-0.2%	$2.5M+0.7%	$2.5M
Income Tax	-$184K-105.6%	$3.3M+753.9%	$386K+138.9%	-$993K-211.3%	$892K+164.3%	-$1.4M-171.3%	$1.9M+651.8%	-$353K
Net Income	-$6.6M+18.0%	-$8.1M+26.7%	-$11.0M-156.0%	$19.7M+295.2%	-$10.1M+2.3%	-$10.3M+43.5%	-$18.3M-9155.0%	$202K
EPS (Diluted)	$-0.05	N/A	$-0.09-400.0%	$0.03+137.5%	$-0.08	N/A	$-0.15-50.0%	$-0.10

SKIN Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$499.8M-27.1%	$685.7M-26.2%	$929.1M-7.4%	$1.0B-17.7%	$1.2B+447.0%	$222.8M
Current Assets	$309.5M-35.1%	$477.1M-31.7%	$698.3M-10.9%	$783.3M-21.7%	$1.0B+1593.7%	$59.1M
Cash & Equivalents	$232.7M-37.1%	$370.1M-29.2%	$523.0M-8.0%	$568.2M-37.0%	$901.9M+9407.5%	$9.5M
Inventory	$48.0M-30.5%	$69.1M-24.3%	$91.3M-16.7%	$109.7M+211.0%	$35.3M+52.0%	$23.2M
Accounts Receivable	$21.7M-21.4%	$27.6M-49.5%	$54.7M-28.5%	$76.5M+63.4%	$46.8M+152.1%	$18.6M
Goodwill	$126.6M+2.5%	$123.5M-1.8%	$125.8M+1.0%	$124.6M+0.7%	$123.7M+25.5%	$98.5M
Total Liabilities	$438.7M-30.8%	$633.9M-27.1%	$869.7M+4.0%	$836.0M-8.8%	$916.5M+262.6%	$252.8M
Current Liabilities	$186.3M+173.3%	$68.2M-40.7%	$115.0M+60.4%	$71.7M-6.2%	$76.4M+147.1%	$30.9M
Long-Term Debt	N/A	$552.2M	N/A	N/A	N/A	N/A
Total Equity	$61.1M+17.9%	$51.8M-12.8%	$59.4M-64.4%	$167.1M-43.9%	$298.0M+1075.0%	-$30.6M
Retained Earnings	-$517.5M-1.9%	-$508.0M-6.1%	-$478.9M-26.4%	-$378.8M+9.5%	-$418.7M-860.3%	-$43.6M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$473.2M-5.3%	$499.8M-0.8%	$503.6M-0.8%	$507.6M-24.7%	$673.8M-1.7%	$685.7M-2.0%	$699.5M-1.7%	$711.8M
Current Assets	$277.7M-10.3%	$309.5M+0.4%	$308.4M+0.7%	$306.1M-34.8%	$469.4M-1.6%	$477.1M-1.6%	$485.0M-0.9%	$489.6M
Cash & Equivalents	$204.4M-12.2%	$232.7M+6.1%	$219.4M+3.5%	$212.0M-43.2%	$373.0M+0.8%	$370.1M+3.1%	$358.9M+2.7%	$349.5M
Inventory	$47.7M-0.7%	$48.0M-14.5%	$56.1M-5.1%	$59.2M-9.8%	$65.6M-5.0%	$69.1M-5.9%	$73.4M-4.8%	$77.1M
Accounts Receivable	$18.6M-14.4%	$21.7M-2.1%	$22.2M-11.3%	$25.0M+7.7%	$23.3M-15.9%	$27.6M-23.8%	$36.3M-12.4%	$41.4M
Goodwill	$126.2M-0.3%	$126.6M+0.1%	$126.5M+0.2%	$126.3M+1.6%	$124.3M+0.6%	$123.5M-1.6%	$125.5M+0.5%	$124.8M
Total Liabilities	$418.0M-4.7%	$438.7M+0.2%	$438.0M+1.0%	$433.6M-30.9%	$627.8M-1.0%	$633.9M-0.9%	$639.8M-0.4%	$642.6M
Current Liabilities	$155.2M-16.7%	$186.3M+200.9%	$61.9M+4.1%	$59.4M-5.4%	$62.8M-7.8%	$68.2M-7.8%	$73.9M-2.0%	$75.4M
Long-Term Debt	N/A	N/A	$363.4M+0.1%	$363.1M	N/A	$552.2M	N/A	N/A
Total Equity	$55.2M-9.5%	$61.1M-7.0%	$65.7M-11.3%	$74.0M+60.7%	$46.1M-11.1%	$51.8M-13.3%	$59.7M-13.7%	$69.2M
Retained Earnings	-$524.1M-1.3%	-$517.5M-1.6%	-$509.4M-2.2%	-$498.3M+3.8%	-$518.1M-2.0%	-$508.0M-2.1%	-$497.6M-3.8%	-$479.3M

SKIN Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$37.5M+132.3%	$16.1M-25.8%	$21.8M+120.4%	-$106.6M-275.9%	-$28.4M-128.1%	-$12.4M
Capital Expenditures	$303K-59.9%	$756K-80.2%	$3.8M-64.7%	$10.8M-3.2%	$11.2M+219.9%	$3.5M
Free Cash Flow	$37.2M+141.8%	$15.4M-14.2%	$17.9M+115.3%	-$117.4M-196.9%	-$39.6M-148.2%	-$15.9M
Investing Cash Flow	-$5.2M+24.0%	-$6.8M+78.4%	-$31.5M-67.0%	-$18.9M+50.0%	-$37.7M-888.5%	-$3.8M
Financing Cash Flow	-$174.9M-10.5%	-$158.3M-322.8%	-$37.4M+81.8%	-$205.2M-121.4%	$959.0M+5148.4%	$18.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$0	$0-100.0%	$30.2M-81.2%	$160.0M	$0-100.0%	$154K

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$5.6M-136.5%	$15.2M+57.5%	$9.6M0.0%	$9.6M+222.0%	$3.0M-81.8%	$16.5M+59.7%	$10.3M+66.3%	$6.2M
Capital Expenditures	$224K+61.2%	$139K+414.8%	$27K-70.7%	$92K+104.4%	$45K-39.2%	$74K+1750.0%	$4K-98.8%	$334K
Free Cash Flow	-$5.8M-138.4%	$15.1M+56.5%	$9.6M+0.7%	$9.6M+223.8%	$3.0M-82.0%	$16.4M+59.0%	$10.3M+75.7%	$5.9M
Investing Cash Flow	-$1.6M-19.3%	-$1.4M-27.5%	-$1.1M+30.2%	-$1.6M-35.5%	-$1.1M-32.8%	-$862K+58.8%	-$2.1M-2.6%	-$2.0M
Financing Cash Flow	-$20.9M-3983.2%	-$512K+36.2%	-$803K+99.5%	-$173.4M-69244.4%	-$250K+67.5%	-$770K-277.5%	-$204K+99.8%	-$98.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SKIN Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	65.3%+10.8pp	54.5%+15.6pp	39.0%-29.0pp	68.0%-0.6pp	68.7%+12.2pp	56.4%
Operating Margin	-6.9%+13.4pp	-20.3%+12.6pp	-32.9%-25.8pp	-7.1%+8.3pp	-15.3%-0.9pp	-14.4%
Net Margin	-3.2%+5.5pp	-8.7%+16.4pp	-25.1%-37.2pp	12.1%-133.5pp	145.6%+170.1pp	-24.5%
Return on Equity	-15.6%+40.6pp	-56.2%+112.4pp	-168.6%-195.0pp	26.5%-100.6pp	127.1%	N/A
Return on Assets	-1.9%+2.3pp	-4.2%+6.5pp	-10.8%-15.2pp	4.4%-26.7pp	31.1%+44.2pp	-13.1%
Current Ratio	1.66-5.3	7.00+0.9	6.07-4.9	10.92-2.2	13.09+11.2	1.91
Debt-to-Equity	7.19-3.5	10.66-4.0	14.64+9.6	5.00+1.9	3.08+11.3	-8.27
FCF Margin	12.4%+7.8pp	4.6%+0.1pp	4.5%+36.6pp	-32.1%-16.9pp	-15.2%-1.8pp	-13.4%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	68.5%+4.1pp	64.4%-0.2pp	64.6%+1.8pp	62.8%-7.0pp	69.8%+7.1pp	62.7%+11.1pp	51.6%+6.4pp	45.2%
Operating Margin	-2.8%-3.0pp	0.2%+9.0pp	-8.8%-5.4pp	-3.5%+13.8pp	-17.3%-8.7pp	-8.6%+18.7pp	-27.3%-2.9pp	-24.4%
Net Margin	-10.2%-0.4pp	-9.8%+5.8pp	-15.6%-40.8pp	25.2%+39.7pp	-14.5%-2.1pp	-12.4%+10.8pp	-23.2%-23.4pp	0.2%
Return on Equity	-12.0%+1.2pp	-13.2%+3.6pp	-16.8%-43.4pp	26.6%+48.6pp	-21.9%-2.0pp	-19.9%+10.7pp	-30.6%-30.9pp	0.3%
Return on Assets	-1.4%+0.2pp	-1.6%+0.6pp	-2.2%-6.1pp	3.9%+5.4pp	-1.5%+0.0pp	-1.5%+1.1pp	-2.6%-2.6pp	0.0%
Current Ratio	1.79+0.1	1.66-3.3	4.98-0.2	5.15-2.3	7.47+0.5	7.00+0.4	6.56+0.1	6.49
Debt-to-Equity	7.57+0.4	7.19+1.7	5.53+0.6	4.91-8.7	13.63+3.0	10.66-0.1	10.71+1.4	9.29
FCF Margin	-8.9%-27.2pp	18.3%+4.7pp	13.6%+1.4pp	12.2%+8.0pp	4.2%-15.4pp	19.6%+6.6pp	13.1%+6.6pp	6.5%

Similar Companies

Helen Of Troy Ltd HELE

$544.9M

Honest Company, Inc. HNST

$351.2M

Nu Skin Enter NUS

$304.9M

Yatsen Hldg Ltd YSG

$238.4M

Edgewell Pers Care Co EPC

$768.6M

Frequently Asked Questions

What is Skinhealth Systems Inc's annual revenue?

Skinhealth Systems Inc (SKIN) reported $300.8M in total revenue for fiscal year 2025. This represents a -10.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Skinhealth Systems Inc's revenue growing?

Skinhealth Systems Inc (SKIN) revenue declined by 10% year-over-year, from $334.3M to $300.8M in fiscal year 2025.

Is Skinhealth Systems Inc profitable?

No, Skinhealth Systems Inc (SKIN) reported a net income of -$9.5M in fiscal year 2025, with a net profit margin of -3.2%.

What is Skinhealth Systems Inc's EBITDA?

Skinhealth Systems Inc (SKIN) had EBITDA of $33K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Skinhealth Systems Inc's gross margin?

Skinhealth Systems Inc (SKIN) had a gross margin of 65.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Skinhealth Systems Inc's operating margin?

Skinhealth Systems Inc (SKIN) had an operating margin of -6.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Skinhealth Systems Inc's net profit margin?

Skinhealth Systems Inc (SKIN) had a net profit margin of -3.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Skinhealth Systems Inc's return on equity (ROE)?

Skinhealth Systems Inc (SKIN) has a return on equity of -15.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Skinhealth Systems Inc's free cash flow?

Skinhealth Systems Inc (SKIN) generated $37.2M in free cash flow during fiscal year 2025. This represents a 141.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Skinhealth Systems Inc's operating cash flow?

Skinhealth Systems Inc (SKIN) generated $37.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Skinhealth Systems Inc's total assets?

Skinhealth Systems Inc (SKIN) had $499.8M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Skinhealth Systems Inc's capital expenditures?

Skinhealth Systems Inc (SKIN) invested $303K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Skinhealth Systems Inc spend on research and development?

Skinhealth Systems Inc (SKIN) invested $5.6M in research and development during fiscal year 2025.

How many shares does Skinhealth Systems Inc have outstanding?

Skinhealth Systems Inc (SKIN) had 128M shares outstanding as of fiscal year 2025.

What is Skinhealth Systems Inc's current ratio?

Skinhealth Systems Inc (SKIN) had a current ratio of 1.66 as of fiscal year 2025, which is generally considered healthy.

What is Skinhealth Systems Inc's debt-to-equity ratio?

Skinhealth Systems Inc (SKIN) had a debt-to-equity ratio of 7.19 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Skinhealth Systems Inc's return on assets (ROA)?

Skinhealth Systems Inc (SKIN) had a return on assets of -1.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Skinhealth Systems Inc's Piotroski F-Score?

Skinhealth Systems Inc (SKIN) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Skinhealth Systems Inc's earnings high quality?

Skinhealth Systems Inc (SKIN) has an earnings quality ratio of -3.95x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Skinhealth Systems Inc cover its interest payments?

Skinhealth Systems Inc (SKIN) has an interest coverage ratio of -1.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Skinhealth Systems Inc?

Skinhealth Systems Inc (SKIN) scores 14 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.